glp 1 mochi health MY NEW GLP-1 PROVIDER IS..... HEALTH; GLP-1 JOURNEY AGAIN, HOW TO GET GLP-1 SUPPORT Mochi Health: Specific Patient Profiles

Severe gastrointestinal disease, particularly gastroparesis, may alter both efficacy and tolerability and requires careful consideration

Currently, the SURPASS-CVOT trial is evaluating the impact of dulaglutide and tirzepatide on cardiovascular events in patients with T2D (NCT04255433)

For instance, Black patients are 19% less likely to be prescribed these drugs than white patients, and Latino patients are 9% less likely to receive prescriptions (Kaplan, 2024)

The increasing cost of GLP-1 drugs is a key consideration for employers managing pharmacy spend

What are Semaglutide GLP-1 injections

According to research published in Diabetes Care, microdosing offers a tailored solution to maximize therapeutic benefit, minimize adverse effects, and address medication availability concerns